Abstract
The Comprehensive in vitro Proarrhythmia Assay (CiPA) aim is to improve specificity compared to in vitro hERG and in vivo QT studies. Automated patch clamp (APC) instruments are increasingly adopted for cardiac safety measurements on hERG, NaV1.5 and CaV1.2, thus requiring standardized experimental protocols and technical specifications, e.g. temperature control, accessibility of recording solutions to allow for sample collection or Liquid Junction Potential (LJP) correction for accurate voltage control.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call